Table 1.
Baseline characteristics.
| Patient characteristics | No. of patients (%) (N=426) |
|---|---|
| Age (years) | 63.5+15.0 |
| Tumor stage | |
| I | 230 (54.0%) |
| II | 153 (35.9%) |
| III | 43 (10.1%) |
| Histologic grade | |
| Well differentiated | 77 (18.1%) |
| Moderately differentiated | 163 (38.3%) |
| Poorly differentiated | 171 (40.1%) |
| Missing | 15 (3.5%) |
| Menopausal status | |
| Premenopausal | 297 (69.7%) |
| Postmenopausal | 195 (45.8%) |
| Tumor size | |
| ≤2cm | 297 (69.7%) |
| >2cm | 123 (28.9%) |
| Missing | 6 (1.4%) |
| Lymph node status | |
| Positive | 135 (31.7%) |
| Negative | 238 (55.9%) |
| Not examined | 53 (12.48%) |
| Surgery | |
| No surgery | 11 (2.6%) |
| Masectomy | 396 (93.0%) |
| Lumpectomy | 19 (4.4%) |
| Chemotherapy | 201 (47.21%) |
| Radiotherapy | 252 (59.2%) |
| Hormone replacement therapy | 279 (65.5%) |
| Herceptin | 29 (6.8%) |
| Tamoxifen | 210 (49.3%) |
| Aromatase Inhibitor | 154 (36.2%) |